CDKL3 准ATG5,以加剧恶性黑色素瘤的进展
Qi Chen1, Wenyuan Yu1, Yifei Gu1
1Department of Plastic and Cosmetic Surgury, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Molecular carcinogenesis
|June 26, 2025
概括
循环素依赖性酶类3 (CDKL3) 通过促进细胞增殖和迁移来驱动黑色素瘤的进展. 向CDKL3可能为晚期恶性黑色素瘤患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 皮肤病学 皮肤病学
背景情况:
- 恶性黑色素瘤是一种具有转移潜力的重大皮肤癌.
- 目前尚不清楚林依赖类激酶3 (CDKL3) 在黑色素瘤发病过程中的作用.
研究的目的:
- 为了研究CDKL3在恶性黑色素瘤中的表达和功能.
- 阐明CDKL3在黑色素瘤进展中的潜在机制.
主要方法:
- 临床黑色素瘤组织和正常皮肤中的CDKL3表达分析.
- 在体外和体内研究使用CDKL3缺陷黑色素瘤细胞模型.
- 细胞增殖,迁移,入侵和细胞亡的评估.
- 研究CDKL3与与自相关的5 (ATG5) 的相互作用.
主要成果:
- 在恶性黑色素瘤组织中,CDKL3的高调显著,特别是在晚期阶段.
- 降低CDKL3可以抑制黑色素瘤细胞的增殖,迁移和入侵,同时诱导细胞亡.
- 在体内,CDKL3促进黑色素瘤瘤的发生.
- CDKL3通过ATG5依赖的途径增强黑色素瘤细胞自.
结论:
- CDKL3在促进恶性黑色素瘤进展方面发挥着至关重要的作用.
- CDKL3代表了黑色素瘤进展的潜在生物标志物.
- CDKL3成为黑色素瘤治疗的潜在治疗点.
相关概念视频
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K


